Updates in the Field of Multiple Sclerosis 2026

The Yale Multiple Sclerosis Symposium, taking place on May 8, 2026, at the New Haven Lawn Club in New Haven, Connecticut, will provide clinicians with an in-depth update on the rapidly evolving field of Multiple Sclerosis (MS). MS remains one of the most common neurological disorders causing disability in young adults, with more than one million individuals currently affected in the United States.

Advances in disease phenotyping, diagnostic imaging, and therapeutic strategies continue to reshape the management of MS, creating an ongoing need for clinicians to stay current with emerging evidence and evolving standards of care. This symposium will review recent scientific developments, highlight best practices in clinical management, and equip providers with practical strategies to improve outcomes and enhance the quality of care for individuals living with MS.

1. Review updates in the biologic basis of multiple sclerosis development and progression.
2. Demonstrate the utility of ancillary testing in the diagnosis and management of multiple sclerosis.
3. Identify novel and up-in-coming disease-modifying therapies used for the treatment of multiple sclerosis.
4. Describe how to approach and manage sexual and urologic health in patients with multiple sclerosis.
5. Identify advancements in adaptive devices available to patients with multiple sclerosis and neurologic disability.

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The Yale School of Medicine designates this enduring material for a maximum of 8.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
It is the policy of Yale School of Medicine, Continuing Medical Education (CME), to ensure balance, independence, objectivity, and scientific rigor in all its educational programs.  All individuals involved in the development and presentation of Accredited Continuing Education activities are required to disclose all financial relationship(s) with ineligible companies that has occurred within the past 24 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. This information is disclosed to all activity participants prior to the commencement of the educational activity.

Mitigation of Relevant Financial Relationships

Yale Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Aaron Bower, MD
Assistant Professor
Yale School of Medicine
Cheshire, CT

Course Director

Nothing to disclose

Annalisa Morgan, MD
Fellow Physician
Yale School of Medicine
New Haven, CT

Course Director

Other: Travel Fees to Investigator Meeting for Research Study-Roche (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech (Relationship has ended)|Other: MDAngle video recordings-Medscape (Relationship has ended)

David Hafler, MD
William S. and Lois Stiles Edgerly Professor of Neurology and Professor of Immunobiology Chair, Department of Neurology Neurologist-in-Chief, Yale New Haven Hospital
Yale School of Medicine
New Haven, CT

Faculty

Grant or research support-Bristol Myers Squibb|Grant or research support-Genentech|Consulting Fee-Genentech (Relationship has ended)|Consulting Fee-GlaxoSmithKline|Grant or research support-Sanofi|Grant or research support-Roche|Grant or research support-Arcus|Consulting Fee-Biogen (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Neximmune (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Viela Bio

Commercial Support Opportunities

Exhibit Display and other commercial support opportunities will be available for this CME program, with full details to be released in the new year.

Please note, as of January 2026, all exhibit and commercial support participation for Yale CME events must be pre-approved by the Yale Office of General Counsel and will require both a fully executed Sponsorship Agreement and a company W-9. Companies and their representatives should factor these requirements into their internal review and approval timelines. A firm submission deadline will be included to ensure all agreements are completed in time for participation.